Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Перспективы клинического применения новой фиксированной комбинации – препарата Ко-Эксфорж в лечении артериальной гипертонии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В представленном обзоре рассматриваются вопросы улучшения контроля у пациентов уровней артериального давления (АД) и лечения артериальной гипертонии (АГ). Анализируются причины низкой приверженности пациентов к лечению и достоинства комбинированной антигипертензивной терапии. Приведены данные целесообразности более широкого применения фиксированных комбинаций антигипертензивных препаратов (АГП). Представлены исследования, демонстрирующие высокую эффективность и безопасность новой тройной фиксированной комбинации препаратов амлодипин/валсартан/гидрохлоротиазид (ГХТ). Обозначены группы пациентов с АГ, в терапии которых следует более активно применять данную комбинацию препаратов.
Ключевые слова: артериальная гипертония, амлодипин, валсартан, гидрохлоротиазид, комбинированная терапия.
Ключевые слова: артериальная гипертония, амлодипин, валсартан, гидрохлоротиазид, комбинированная терапия.
________________________________________________
This review is concerned with improving of blood pressure (BP) control in patients with arterial hypertension (AH). The reasons for the low treatment compliance and combined antihypertensive therapy benefits are analyzed. Data for futility of an extended use of antihypertensive drugs (AHD) fixed combinations are given. Studies demonstrating high efficacy and safety of a new triple fixed combination of amlodipine, valsartan and hydrochlorothiazide (HCT) are presented as well. Patients with hypertension, which should more actively use this combination of drugs, are signified.
Key words: hypertension, amlodipine, valsartan, hydrochlorothiazide, combination therapy.
Полный текст
Список литературы
1. Mancia G, DeBacker G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1442–536.
2. World Health Organization. Cardiovascular diseases fact sheet [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs317/r=en/index.html [Accessed 2009 Sep 9]
3. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
4. Materson BL, Reda DL, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertension agents with placebo. N Eng J Med 1993; 328: 914–21.
5. Бубнова М.Г., Оганов Р.Г. Лечение пациентов с артериальной гипертонией и дополнительными факторами риска в клинической практике. Программа наблюдения ПРОГНОЗ. Тер. арх. 2009; 81 (9): 1–4.
6. Бубнова М.Г., Оганов Р.Г. Программа наблюдения ПРОГНОЗ у пациентов с артериальной гипертонией и дополнительными факторами риска мозгового инсульта в клинической практике. Фармакотерапия в кардиологии и ангиологии. 2010; 3: 52–8.
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000 JAMA 2003; 290:199–206.
8. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North Am settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404.
9. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288: 2421–31.
10. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calciumantagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST) – a randomized controlled trial. JAMA 2003; 290: 2805–16.
11. Dezii CM, A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl. 9): 2–6.
12. Wald DS, Law M, Morris JK et al. Combination Therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 Pacticipants from 42 Trials. Am J of Medicine 2009; 112: 290–300.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–34.
14. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide. Fixed-Dose Combination in Hypertension. Am J Cardiovasc Drug 2009; 9 (6): 411–8.
15. Calhoun DA, Lacourciere Y, Chiang YT et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorthiazide: a randomized clinical trial. J Hypertension 2009; 54 (1): 32–9.
16. Calhoun DA, Crikerlair NA, Yen J, Glazer RD. Amlodipine/Valsartan/Hydrochlorthiazide Triple Combination Therapy in Moderate/Sever Hypertension: Secondary Analyses Evaluating Efficacy and Safety Adv Ther 2009; 26 (11): 1012–23.
17. Lacourciere Y, Glazer RD, Yen J et al. Twenty-four hour ambulatory BP control of therapy with anlodipine/valsartan/HCTZ triple combination compared to dual therapy in patients with moderate to severe hypertension [abstract no.P26.301]. J Hypertens 2009; 27 (Suppl. 4): S271.
18. Calhoun D, Glazer R, Yen J et al. Effect of age, gender, race and ethnicity on efficacy on efficacy of amlodipine/valsartan/hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension [abstract no.P11.269]. J Hypertens 2009; 27 (Suppl. 4): S119.
19. Zappe DH, Crikelair N, Papst CC et al. Efficacy of amlodipine/valsartan/hydrochlorothiazide triple combination in patients whose blood pressure was not controlled with dual combinations: the PROMPT extension study [abstract no.P11.304]. J Hypertension 2009; 27 (Suppl. 4): S12.
20. White WB, Calhoun DA, Samuel R et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The Valsartan hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve optimal Therapeutic Effect (Val-DICTATE) trial. J Clin Hypertension 2008; 10 (6): 450–8.
21. Flack JM,Calhoun DA, Satlin L et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertension 2009; 23 (7): 479–89.
22. Destro M, Luckow A, Samson M et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicentre study: the EX-EFFeCTS study. J Am Society Hypertension 2008; 2 (4): 294–302.
23. Pool JI, Glazer R., Weinberger M et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-bind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61–73.
24. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with in antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumetihazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
25. Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии. 2010; 4: 14–20.
2. World Health Organization. Cardiovascular diseases fact sheet [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs317/r=en/index.html [Accessed 2009 Sep 9]
3. Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
4. Materson BL, Reda DL, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertension agents with placebo. N Eng J Med 1993; 328: 914–21.
5. Бубнова М.Г., Оганов Р.Г. Лечение пациентов с артериальной гипертонией и дополнительными факторами риска в клинической практике. Программа наблюдения ПРОГНОЗ. Тер. арх. 2009; 81 (9): 1–4.
6. Бубнова М.Г., Оганов Р.Г. Программа наблюдения ПРОГНОЗ у пациентов с артериальной гипертонией и дополнительными факторами риска мозгового инсульта в клинической практике. Фармакотерапия в кардиологии и ангиологии. 2010; 3: 52–8.
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000 JAMA 2003; 290:199–206.
8. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North Am settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393–404.
9. Wright JT, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288: 2421–31.
10. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calciumantagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST) – a randomized controlled trial. JAMA 2003; 290: 2805–16.
11. Dezii CM, A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl. 9): 2–6.
12. Wald DS, Law M, Morris JK et al. Combination Therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 Pacticipants from 42 Trials. Am J of Medicine 2009; 112: 290–300.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–34.
14. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide. Fixed-Dose Combination in Hypertension. Am J Cardiovasc Drug 2009; 9 (6): 411–8.
15. Calhoun DA, Lacourciere Y, Chiang YT et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorthiazide: a randomized clinical trial. J Hypertension 2009; 54 (1): 32–9.
16. Calhoun DA, Crikerlair NA, Yen J, Glazer RD. Amlodipine/Valsartan/Hydrochlorthiazide Triple Combination Therapy in Moderate/Sever Hypertension: Secondary Analyses Evaluating Efficacy and Safety Adv Ther 2009; 26 (11): 1012–23.
17. Lacourciere Y, Glazer RD, Yen J et al. Twenty-four hour ambulatory BP control of therapy with anlodipine/valsartan/HCTZ triple combination compared to dual therapy in patients with moderate to severe hypertension [abstract no.P26.301]. J Hypertens 2009; 27 (Suppl. 4): S271.
18. Calhoun D, Glazer R, Yen J et al. Effect of age, gender, race and ethnicity on efficacy on efficacy of amlodipine/valsartan/hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension [abstract no.P11.269]. J Hypertens 2009; 27 (Suppl. 4): S119.
19. Zappe DH, Crikelair N, Papst CC et al. Efficacy of amlodipine/valsartan/hydrochlorothiazide triple combination in patients whose blood pressure was not controlled with dual combinations: the PROMPT extension study [abstract no.P11.304]. J Hypertension 2009; 27 (Suppl. 4): S12.
20. White WB, Calhoun DA, Samuel R et al. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The Valsartan hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve optimal Therapeutic Effect (Val-DICTATE) trial. J Clin Hypertension 2008; 10 (6): 450–8.
21. Flack JM,Calhoun DA, Satlin L et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertension 2009; 23 (7): 479–89.
22. Destro M, Luckow A, Samson M et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicentre study: the EX-EFFeCTS study. J Am Society Hypertension 2008; 2 (4): 294–302.
23. Pool JI, Glazer R., Weinberger M et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-bind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61–73.
24. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with in antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumetihazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
25. Карпов Ю.А., Чазова И.Е., Вигдорчик А.В. от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии. 2010; 4: 14–20.
Авторы
М.Г.Бубнова
ФГУ Государственный научно-исследовательский Центр профилактической медицины Минздравсоцразвития РФ
mbubnova@gnicpm.ru
ФГУ Государственный научно-исследовательский Центр профилактической медицины Минздравсоцразвития РФ
mbubnova@gnicpm.ru
________________________________________________
M.G.Bubnova
State Research Center for Preventive Medicine. State Federal Agency for Health and Social Development. Moscow
mbubnova@gnicpm.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.